CORD-19:2008f024274c53b0de1276f4047a6a641813fd98 / 691703-691855 JSONTXT

Annnotations TAB JSON ListView MergeView

    CORD-19-Sentences

    {"project":"CORD-19-Sentences","denotations":[{"id":"T98989","span":{"begin":0,"end":152},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Sensitivity analyses showed that TEL/AMC/LEV had superior health outcomes even when only 5% of in vitro resistant organisms were also resistant in vivo."}

    CORD-19_Custom_license_subset

    {"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T131","span":{"begin":0,"end":152},"obj":"Sentence"}],"text":"Sensitivity analyses showed that TEL/AMC/LEV had superior health outcomes even when only 5% of in vitro resistant organisms were also resistant in vivo."}

    CORD-19-PD-MONDO

    {"project":"CORD-19-PD-MONDO","denotations":[{"id":"T6356","span":{"begin":37,"end":40},"obj":"Disease"}],"attributes":[{"id":"A6356","pred":"mondo_id","subj":"T6356","obj":"http://purl.obolibrary.org/obo/MONDO_0015168"}],"text":"Sensitivity analyses showed that TEL/AMC/LEV had superior health outcomes even when only 5% of in vitro resistant organisms were also resistant in vivo."}